Cargando…

Study on the correlation between the concentration of plasma lipoprotein-associated phospholipase A2 and coronary heart disease

OBJECTIVE: This study explores the correlation between plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) and coronary heart disease (CHD) by comparing the level of plasma Lp-PLA2 in the plasma of patients with different types of CHD. METHODS: Blood samples were collected from 56 patients diag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cen, Jin-Ming, Cheng, Jie, Xiong, Qing-Yuan, Mei, Bai-Qiang, Cai, Wei-Biao, Yang, Xi-Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	KeAi Publishing 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643570/ https://www.ncbi.nlm.nih.gov/pubmed/29062994 http://dx.doi.org/10.1016/j.cdtm.2015.02.009

Ejemplares similares

Relationship between Plasma Lipoprotein-Associated Phospholipase A2 Concentrations and Apolipoprotein in Stable Coronary Artery Disease Patients
por: Ling, Yang, et al.
Publicado: (2020)

Increased plasma lipoprotein-associated phospholipase A2 levels are associated with coronary slow flow
por: Ding, Yao-dong, et al.
Publicado: (2020)

Association of Lipoprotein-Associated Phospholipase A(2) with Characteristics of Vulnerable Coronary Atherosclerotic Plaques
por: Liu, Yu-Sheng, et al.
Publicado: (2011)

Plasma concentration of atorvastatin metabolites correlates with low‐density lipoprotein cholesterol reduction in patients with coronary heart disease
por: Sverre, E., et al.
Publicado: (2023)

Correlation between plasma lipoprotein-associated phospholipase A(2) and peripheral arterial disease
por: LI, SHUAI-BING, et al.
Publicado: (2013)

Plasma Lipoprotein-associated Phospholipase A2 in Patients with Metabolic Syndrome and Carotid Atherosclerosis
por: Gong, Hui-ping, et al.
Publicado: (2011)

The correlation between lipoprotein associated phospholipase A(2) and central overweight status
por: Chen, Yi-Hsuan, et al.
Publicado: (2021)

An association study between genetic polymorphisms related to lipoprotein-associated phospholipase A(2) and coronary heart disease
por: XU, LIMIN, et al.
Publicado: (2013)

Plasma Lipoprotein-Associated Phospholipase A2 Affects Cognitive Impairment in Patients with Cerebral Microbleeds
por: Liu, Lu, et al.
Publicado: (2023)

Correlation of lipoprotein-associated phospholipase A2 and cerebral microbleeds in patients with acute ischaemic stroke
por: Zhang, Xiaojiu, et al.
Publicado: (2022)

Is lipoprotein-associated phospholipase A(2) correlated with cardiovascular risk in European women?
por: Hirschler, V.
Publicado: (2013)

Lipoprotein-associated phospholipase A2 and oxidized low-density lipoprotein in young patients with acute coronary syndrome in China
por: Huang, Yuli, et al.
Publicado: (2017)

The relationship of lipoprotein-associated phospholipase A2 activity with the seriousness of coronary artery disease
por: Zhang, Hao, et al.
Publicado: (2020)

Lipoprotein-Associated Phospholipase A(2) Activity and Incident Coronary Heart Disease Among Men and Women With Type 2 Diabetes
por: Hatoum, Ida J., et al.
Publicado: (2010)

Effects of canola or olive oil on plasma lipids, lipoprotein-associated phospholipase A(2) and inflammatory cytokines in patients referred for coronary angiography
por: Khandouzi, Nafiseh, et al.
Publicado: (2020)

Association of Lipoprotein-associated Phospholipase A2 with Coronary Calcification among American and Japanese Men
por: El-Saed, Aiman, et al.
Publicado: (2007)

Effect of intensive insulin treatment on plasma levels of lipoprotein-associated phospholipase A(2) and secretory phospholipase A(2) in patients with newly diagnosed type 2 diabetes
por: Lin, Xiu-hong, et al.
Publicado: (2016)

Lipoprotein‐Associated Phospholipase A(2) Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease
por: Wallentin, Lars, et al.
Publicado: (2016)

Lipoprotein‐associated phospholipase A2: The story continues
por: Huang, Fubao, et al.
Publicado: (2019)

The Relationship Between Lipoprotein-Associated Phospholipase-A2 and Coronary Artery Aneurysm in Children With Kawasaki Disease
por: Cheng, Zhenli, et al.
Publicado: (2022)

Plasma Lipoprotein-Associated Phospholipase A(2) Levels Correlated with the Cardio-Ankle Vascular Index in Long-Term Type 2 Diabetes Mellitus Patients
por: Kotani, Kazuhiko
Publicado: (2016)

Lipoprotein-Associated Phospholipase A(2) Is Related to Plaque Stability and Is a Potential Biomarker for Acute Coronary Syndrome
por: Chung, Hyemoon, et al.
Publicado: (2014)

Change in lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndrome
por: Li, Jingwei, et al.
Publicado: (2018)

Diabetes status modifies the long-term effect of lipoprotein-associated phospholipase A2 on major coronary events
por: Siddiqui, Moneeza K., et al.
Publicado: (2021)

Lipoprotein-associated phospholipase A2, homocysteine, and Alzheimer's disease
por: Doody, Rachelle S., et al.
Publicado: (2015)

Elevated lipoprotein(a) and lipoprotein-associated phospholipase A(2) are associated with unfavorable functional outcomes in patients with ischemic stroke
por: Jiang, Xue, et al.
Publicado: (2021)

Negative correlation between early recovery and lipoprotein-associated phospholipase A2 levels after intravenous thrombolysis
por: Li, Yanzheng, et al.
Publicado: (2022)

Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies
Publicado: (2010)

Alteration in lipoprotein-associated phospholipase A2 levels during acute coronary syndrome and its relationship to standard biomarkers
por: Ostadal, Petr, et al.
Publicado: (2012)

Lipoprotein-Associated Phospholipase A2 Activity Predicts Cardiovascular Events in High Risk Coronary Artery Disease Patients
por: Maiolino, Giuseppe, et al.
Publicado: (2012)

Lipoprotein-associated phospholipase A2 levels, endothelial dysfunction and arterial stiffness in patients with stable coronary artery disease
por: Mourouzis, Konstantinos, et al.
Publicado: (2021)

The Prognostic Value of Lipoprotein-Associated Phospholipase A(2) in the Long-Term Care of Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
por: Yang, Lijiao, et al.
Publicado: (2017)

Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, Reduces Rho Kinase Activity in Atherosclerosis
por: Zhang, Juan, et al.
Publicado: (2016)

Relationship of lipoprotein-associated phospholipase A2(Lp-PLA2) and periprocedural myocardial injury in patients undergoing elective percutaneous coronary intervention
por: Yin, Yun-jie, et al.
Publicado: (2020)

Correlation Between High-Density Lipoprotein and Monocyte Subsets in Patients with Stable Coronary Heart Disease
por: Jiang, Shaoyan, et al.
Publicado: (2015)

Racial variation in lipoprotein-associated phospholipase A(2 )in older adults
por: Lee, Keane K, et al.
Publicado: (2011)

Secreted phospholipase A(2), lipoprotein hydrolysis, and atherosclerosis: integration with lipidomics
por: Yamamoto, Kei, et al.
Publicado: (2011)

Elevated Lipoprotein-Associated Phospholipase A2 Is Associated With Intracranial Atherosclerosis
por: Wang, Yuan, et al.
Publicado: (2022)

Atherosclerotic Plaque Inflammation Varies Between Vascular Sites and Correlates With Response to Inhibition of Lipoprotein‐Associated Phospholipase A(2)
por: Fenning, Robert S., et al.
Publicado: (2015)

Can Lipoprotein-associated Phospholipase A2 be Used as a Predictor of Long-term Outcome in Patients with Acute Coronary Syndrome?
por: Holst-Albrechtsen, Sine, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_krq29n8qkttp23u58t35pqhatf